

## FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

CIN: L86900AP1993PLC118162

Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

August 14, 2025

To

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

**BSE Scrip Code: 524743** 

National Stock Exchange of India Ltd. Exchange Plaza, 5tll floor Plot No. C/ 1, G Block, Bandra-Kurla Complex Bandra (E),

Mumbai - 400 051

**NSE Symbol: FISCHER** 

Dear Sir/ Madam,

## Sub: Outcome of Board Meeting held on 14th August, 2025

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (14/08/2025):

#### 1. Financial Results:

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Period ended 30/06/2025 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015 ('SEBI Listing Regulations"), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records and for uploading in your website. The aforesaid Unaudited Financial Results are also uploaded on the Company's website <a href="https://www.fischermv.com">www.fischermv.com</a>

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

#### 2. 32<sup>nd</sup> Annual General Meeting:

The 32<sup>nd</sup> Annual General Meeting ('AGM') of the Members of the Company will be held on Monday, 29<sup>th</sup> September 2025 through video conferencing or other audio-visual means.

3. Considered & approved the appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary as Scrutinizer of the Annual General Meeting, to scrutinize the e-voting and remote e-voting process in a fair and transparent manner;

## 4. Closure of Register of Members:

Please note that the share transfer books of the Company will remain closed 23/09/2025 (Tuesday) to 29/09/2025 (Monday) (both days inclusive).



FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

CIN: L86900AP1993PLC118162

Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

- 5. Recommended the Appointment of M/s Nuren Lodaya & Associates Practicing Company Secretary (M No. A60128; COP No. 24248) as Secretarial Auditors of the Company for the term of Five years from the conclusion of 32<sup>nd</sup> Annual General Meeting.
- 6. Noted the Resignation of the Dr. Jacob Thomas, Independent Director (DIN: 10639814) with effect from the closing hours of 14<sup>th</sup> August 2025. Details as required under Regulation30 of the SEBI (LODR) Regulations, 2015 are enclosed herewith as **Annexure 2**

The Board Meeting commenced at 12.45 PM (IST) and concluded at 1.30 PM (IST)

Please take on record.

Thanking You,

Yours Truly,

Thanking You,

For FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited)

**ARAVINDKUMAR V** 

**COMPANY SECRETARY AND COMPLIANCE OFFICER** 

#### FISCHER MEDICAL VENTURES LIMITED (formerly known as Fischer Chemic Limited) CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Visakhapatnam, Andhra Pradesh, India, 530044

 $Corp\ off:\ Level\ 8,\ Prestige\ Palladium\ Bayan,\ No.\ 129-140\ Greams\ Road,\ Chennai,\ Tamil\ Nadu,\ 600006,\ India$ 

Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.06.2025 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

						Ţ					Rs. In Lakhs
		STANDALONE  Quarter Ended			Year Ended		CONSOLIDATED  Quarter Ended			Year Ended	
SL	PARTICULARS	30.06.2025	31.03.2025	30.06.2024	31.03.2025	31.03.2024	30.06.2025	31.03.2025	31.03.2024	31.03.2025	31.03.2024
NO		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)
ı	Revenue From Operations	454.23	521.97	-	521.97	1,152.83	2,344.47	4,917.42	1,012.07	11,069.87	2,098.13
ıı.	Other Income	80.40	64.94	112.23	345.70	75.05	746.64	14.87	74.17	149.20	50.11
III	Total Income (I + II)	534.63	586.90	112.23	867.67	1,227.88	3,091.11	4,932.29	1,086.25	11,219.07	2,148.25
IV	Expenses										
	Cost Of Materials Consumed	-	-	-	-	-	-	-	-	-	1,573.80
	Purchase of Traded Assets	318.59	454.56	-	461.06	1,072.36	758.01	3472.30	1,751.84	9,528.18	7.87
	Changes in inventories of finished goods, by-products and work in progress	-	-	-	(6.50)	-	496.32	458.75	(890.39)	(369.22)	63.74
	Employee Benefits Expense	41.75	4.74	2.53	12.84	5.50	315.77	93.58	39.31	258.13	38.10
	Direct Expenses	-	-	-	-	-	22.09	-	-	-	-
	Depreciation and Amortisation Expenses	8.16	9.86	0.05	12.72	0.08	76.97	51.03	27.72	163.28	18.21
	Finance Costs	130.88	12.41	-	13.17	1.58	66.99	22.63	12.50	46.68	6.76
	Other Expenses	56.81	218.48	8.70	278.30	94.49	326.27	642.46	128.95	1,321.11	228.66
	Total Expenses	556.19	700.05	11.28	771.59	1,174.01	2,062.43	4,740.75	1,069.92	10,948.15	1,937.14
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	(21.56)	(113.15)	100.95	96.08	53.87	1,028.68	191.54	16.32	270.92	211.11
VI	Share of profit/(loss) of Associates	-	-	-	-	-	0.11	(1.53)	(3.61)	(13.29)	-
VI	Exceptional Items	-	-	-	-	-	(11.26)	(8.79)	(5.11)	(35.36)	-
VII	Profit / (Loss) Before Tax (V - VI)	(21.56)	(113.15)	100.95	96.08	53.87	1,017.53	181.22	7.60	222.27	211.11
VIII	Tax Expense										
	Current Tax	-	2.00	(17.00)	(52.00)	(3.00)	(441.62)	(59.35)	(17.00)	(107.95)	(3.00)
	Deferred Tax (Asset) / Liability	(39.38)	27.50	(0.01)	27.64	(10.59)	(75.09)	9.35	(2.32)	11.87	(24.33)
	Tax pertaining to Prevous year	-	(5.40)	-	(5.40)	-				(5.40)	
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	(60.94)	(89.05)	83.94	66.32	40.28	500.82	131.22	(11.71)	120.79	183.78
X	Profit / (Loss) From Discontinued Operations Tax Expense Of Discontinued	-	-	-	-	-	-	-	-	-	-
ΧI	Operations	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) For The Period (IX + XII)	(60.94)	(89.05)	83.94	66.32	40.28	500.82	131.22	(11.71)	120.79	183.78
	Items That Will Not Be Reclassified To Profit / (Loss)										
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	(0.78)	-	(0.78)	-
XIV	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	-	(0.78)	-	(0.78)	-
	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	(60.94)	(89.05)	83.94	66.32	40.28	500.82	130.44	(11.71)	120.01	183.78
XVI	Paid Up Equity Share Capital (Face Value Re.1/-)	6,485.15	6,380.15	5,350.00	6,380.15	6,485.15	6,485.15	6,380.15	5,350.00	6,380.15	6,485.15
XVII	Other Equity Earnings Per Share (EPS)				24,166.26					24,350.14	
	From Continuing Operations &  Discontinued Operations (In Rs.)  Basic	(0.09)	(0.06)	0.16	0.05	0.36	0.09	(0.05)	0.65	0.22	1.65
	Diluted	(0.09)	(0.00)	0.10	0.05	0.30	0.09	(0.05)		0.22	1.03

Notes:

Diluted

1 These unaudited consolidated financial results relate to Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) (the 'Company'), and its Subsidiaries (together the 'Group'), and Associates are prepared by applying Ind AS 110 - "Consolidated Financial Statements",

0.04

0.15

- The above unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 14th August 2025
- 3 Figures for the previous periods have been reclassified, wherver necessary, to conform to the current period's classification.

(0.09)

(0.06)

- 4 The above statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.
- The Statutory Auditor of the Company reviewed the above Standalone and Consolidated Financial Results for the quarter ended 30.06.2025 and the Limited review Report with an unmodified opinion was placed before the Board.

 $/\!/$  BY ORDER OF THE BOARD  $/\!/$ 



0.36

For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

0.64

0.22

1.08

Chairman & Managing Director
DIN: 03137661

(0.05)

0.09



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to date of the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To
The Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

- We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended 30<sup>th</sup> June 2025 and year to date result for the period from 1<sup>st</sup> April 2025 to 30<sup>th</sup> June 2025 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI {Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai - 400 099. Tel : +91 22 6697 2111/12/13, 2837 5522/33 Registered Office : Sethna Buildging, 1st Floor, 216, Shamaldas Gandhi Marg ( Princess Street), Mumbai - 400 002. Tel : +91-22-2201 4884/6807

New Delhi: 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi: 110 001. Tel: +91-11-43543750/23736049

Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabana Lane, Kolkata - 700 020 (West Bengal) Tel: +91-9804879857



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any

material misstatement.

Our Opinion is not modified in respect of these matters.

## For Bilimoria Mehta & Co.

**Chartered Accountants** Firm Reg. No. 101490W

Aakash Himanshu Digitally signed by Aakash Himanshu

Mehta

Mehta

Date: 2025.08.14 12:30:16 +05'30'

## **CA Aakash Mehta**

Partner

Membership no. 165824

UDIN: 25165824BMIILB5613

Place: Mumbai Date: 14-08-2025

: Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andhen (East), Mumbai - 400 099. Tel: +91 22 6697 2111/12/13, 2837 5522/33 Registered Office: Sethna Buildging, 1st Floor, 216, Shamaldas Gandhi Marg ( Princess Street), Mumbai - 400 002. Tel: +91-22-2201 4884/6807

New Delhi: 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi-110 001. Tel: +91-11-43543750/23736049



Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

# To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

- 1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30th June 2025 and consolidated year to date results for the period 1 April 2025, to 30th June 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.
- 5. Based on our review conducted and procedures performed and upon consideration of the review reports of other auditors below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Mumbai : Corporate Office: 507/508, 5th Floor, INIZIO, Cardinal Gracious Road, Chakala, Andheri (East), Mumbai - 400 099. Tel: +91 22 6697 2111/12/13, 2837 5522/33 Registered Office: Sethna Buildging, 1st Floor, 216, Shamaldas Gandhi Marg ( Princess Street), Mumbai - 400 002. Tel: +91-22-2201 4884/6807

New Delhi: 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi: 110 001. Tel: +91-11-43543750/23736049

Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857



6. The accompanying interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets of Rs. 41,539.12 Lakhs as at 30th June 2025, and year-to-date total revenues of Rs 3091.11 lakhs and year-to-date total comprehensive income of Rs 500.82 lakhs, as considered in the Statement. The independent auditor's reports on interim financial results and other financial information of these entities have been furnished to us by management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditors.

Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

Our opinion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

## For Bilimoria Mehta & Co,

**Chartered Accountants** 

ICAI Firm Registration No.: 101490W

Aakash Digita by Aa Himansh Under Himansh Un

Digitally signed by Aakash Himanshu Mehta Date: 2025.08.14 12:29:30 +05'30'

**CA Aakash Mehta** 

Partner

Membership No: 165824 UDIN: 25165824BMIILC4689

Place: Mumbai Date: 14-08-2025

New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel : +91-11-43543750/23736049

Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857



#### **ANNEXURE-1**

## List of Entities included in the statement:

Sr no	<u>Particulars</u>	Stakes	<u>Status</u>		
1	Time Medical International Ventures (India)		Subsidiary		
	Private Limited		-		
2	Time Medical Philippines (Subsidiary of Time	75%	Subsidiary		
	Medical International Ventures (India) Private				
	Limited)				
		200/			
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)		
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)		
5	Flynncare HealthCare Innovations Private	100%	Subsidiary of Fischer		
	Limited		Medical Ventures Limited		
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer		
			Medical Ventures Limited		
7	Fischer Hospitality Sdn. Bdn.	60%	Subsidiary of Fischer		
			Medical Ventures Limited		
8	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer		
			Medical Ventures Limited		
9	FMV HealthCare PTE Ltd.	100%	Subsidiary of Fischer		
			Medical Ventures Limited		
10	FMV Global Innovation PTE Ltd	100%	Subsidiary of Fischer		
			Medical Ventures Limited		

New Delhi : 505 Mercantile House Buildging, 15, Kasturba Gandhi Marg, Connaught Place New Delhi - 110 001. Tel : +91-11-43543750/23736049

Kolkata : Ground Floor, Jyotermoyee Buildging, 27/2, Chakrabaria Lane, Kolkata - 700 020 (West Bengal) Tel : +91-9804879857



#### FISCHER MEDICAL VENTURES LIMITED

(Formerly known as Fischer Chemic Limited) Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032

CIN: L86900AP1993PLC118162

Email: enquiry@fischermv.com | Website: www.fischermv.com | Contact 9080966548

#### **ANNEXURE - 2**

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. EBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	DR. JACOB THOMAS
DIN	10639814
Reason for Change	Resignation as the Director of the Company with effect
	from closure of Business hours on 14th August 2025 due
	to personal reasons and no other material reasons
Date of cessation	Closure of Business hours on 14th August 2025
Term of	Not Applicable
appointment/reappointment;	
Brief profile (in case of	Not Applicable
appointment)	
Disclosure of relationships	No relation with Directors
between Directors	
Other Directorships /	Nil
Memberships (in listed entities in	
case of resignation of	
Independent director)	
The independent director shall,	Dr. Jacob Thomas has confirmed that there are no material
along with the detailed reasons,	reasons for his resignation other than those mentioned in
also provide a confirmation that	his resignation letter
there is no other material	
reasons other than those	
provided.	

\*\*\*